NCT01975935View on ClinicalTrials.gov

Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

April 25, 2016

Study Completion Date

August 18, 2017

Conditions
Diabetes Mellitus Type 2Non-alcoholic Fatty Liver DiseaseObesity
Interventions
DRUG

Amlexanox

25 mg amlexanox tablets blinded by encapsulation

DRUG

Placebo

placebo sham blinded by encapsulation in the same capsules as the study drug arm

Trial Locations (1)

48109

University of Michigan, Ann Arbor

All Listed Sponsors
lead

University of Michigan

OTHER

NCT01975935 - Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients | Biotech Hunter | Biotech Hunter